us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure Show More Show Less Compare false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $117.88

    as of November 18, 2026
  • YTD RETURNS
    16.29%

    as of November 18, 2026
  • Total Net Assets
    $1.05B

    as of November 18, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Overview

Why PPH

  • Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
  • Industry LeadersFavors established industry leaders with meaningful scale
  • Global ScopeProvides exposure to U.S. and international equities for global industry representation

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Performance

Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) 9.48 8.49 17.71 31.59 18.94 11.85 10.78 10.62
PPH (Market Price) 9.37 8.45 17.66 31.57 18.95 11.84 10.78 10.69
MVIS US Listed Pharmaceutical 25 Index 9.49 8.52 17.51 31.39 18.58 11.49 10.51 10.43
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) -3.28 0.50 7.51 23.60 13.35 10.67 8.69 10.00
PPH (Market Price) -3.19 0.67 7.58 23.72 13.37 10.65 8.70 10.09
MVIS US Listed Pharmaceutical 25 Index -3.26 0.55 7.32 23.42 13.00 10.31 8.44 9.81

Holdings

Daily Holdings (%) as of 11/18/2026

Download XLS Get holdings
Total Holdings: 26
Ticker
Holding Name
% of Net Assets
Market Value (US$)
LLY
Eli Lilly & Co
22.95
240,415,977
MRK
Merck & Co Inc
11.72
122,778,376
NVO
Novo Nordisk A/S
5.40
56,626,409
MCK
Mckesson Corp
5.10
53,486,256
PFE
Pfizer Inc
4.71
49,357,764
TEVA
Teva Pharmaceutical Industries Ltd
4.70
49,274,471
COR
Cencora Inc
4.52
47,377,823
BMY
Bristol-Myers Squibb Co
4.31
45,186,028
GSK
Gsk Plc
4.19
43,933,372
ABBV
Abbvie Inc
3.68
38,544,710
AZN
Astrazeneca Plc
3.68
38,517,060
NVS
Novartis Ag
3.64
38,176,072
SNY
Sanofi Sa/France
3.55
37,183,476
HLN
Haleon Plc
3.46
36,199,826
JNJ
Johnson & Johnson
3.30
34,526,274
TAK
Takeda Pharmaceutical Co Ltd
2.94
30,823,250
ZTS
Zoetis Inc
2.81
29,441,214
VTRS
Viatris Inc
1.59
16,694,658
JAZZ
Jazz Pharmaceuticals Plc
1.31
13,732,157
ELAN
Elanco Animal Health Inc
0.55
5,764,664
AXSM
Axsome Therapeutics Inc
0.49
5,177,760
CORT
Corcept Therapeutics Inc
0.42
4,402,554
DFTX
Definium Therapeutics Inc
0.35
3,629,284
OGN
Organon & Co
0.27
2,851,275
PRGO
Perrigo Co Plc
0.11
1,189,290
-USD CASH-
--
-0.00
-5,085
--
Other/Cash
0.24
2,471,903
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Portfolio

Sector Weightings (%) as at 10/31/2026

  • Sector

    % of Net Assets
  • Health Care

    99.90
  • Other/Cash

    0.10

Country Weightings (%) as at 10/31/2026

  • Country

    % of Net Assets
  • United States

    68.70
  • United Kingdom

    11.27
  • Denmark

    5.42
  • Israel

    4.63
  • Switzerland

    3.73
  • France

    3.30
  • Japan

    2.86
  • Other/Cash

    0.10

Fees

Distributions

  as of  11/18/2026


Distribution Frequency

Quarterly


30-Day SEC Yield

1.59%


Distribution Yield

1.22%


12 Month Yield

1.81%

Yield information reflects temporary waivers of expenses and/or fees. Yields would have been reduced had these fees/expenses been included. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Pharmaceutical ETF would have been 1.59% on 11/18/26. Distributions may vary from time to time.

Team

Resources

PPH